Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence

Metabolism and Target Organ Damage, Год журнала: 2025, Номер 5(1)

Опубликована: Март 27, 2025

Fatty liver disease associated with metabolic dysfunction has emerged as a significant global health challenge. This condition often coexists other diseases, such alcohol-related and viral hepatitis, complicating both diagnosis management. To address the limitations of non-alcoholic fatty (NAFLD) classification, two alternative frameworks have been proposed: dysfunction-associated (MAFLD) in 2020 steatotic (MASLD) 2023. A key difference between these definitions is how they consider relation to coexistence conditions. MAFLD adopts dual etiology concept, creating unified classification system that aligns contemporary clinical epidemiological needs. In contrast, MASLD introduces new term, MetALD (metabolic alcohol-related/associated disease), describe patients who excessive alcohol intake. review critically examines clinical, research, implications differing approaches MASLD, offering insights into their potential enhance understanding management multi-etiology diseases.

Язык: Английский

---

Metabolic dysfunction and Kidney Disease Risk in Individuals with MAFLD

Annals of Hepatology, Год журнала: 2025, Номер unknown, С. 101910 - 101910

Опубликована: Март 1, 2025

Язык: Английский

---

Underrepresentation of Arabs in Functional Genetics Studies: Opportunities and Obstacles for Advancing Biology and Human Health

Liver International, Год журнала: 2025, Номер 45(5)

Опубликована: Апрель 4, 2025

A significant challenge to the transnational application of genetics and functional genomic studies is underrepresentation certain populations. In this work, we emphasise that while there are over 500 million Arabs living across 22 countries, they largely underrepresented in genetic studies. Remarkably, only 0.96% Genome-Wide Association Studies (GWAS) include Arab participants. This trend also apparent various other databases, which not limit biological discoveries but exacerbate health inequity. To address urgent issue, propose a comprehensive roadmap aimed at effectively integrating population into research. strategy includes creating regional biobanks establishing advanced research programs translational genomics, as well fostering greater collaboration. Ultimately, approach will pave way for more effective precision medicine equity beyond.

Язык: Английский

---

MAFLD vs. MASLD: a year in review

Expert Review of Endocrinology & Metabolism, Год журнала: 2025, Номер unknown, С. 1 - 12

Опубликована: Апрель 12, 2025

In 2023, metabolic dysfunction-associated steatotic liver disease (MASLD) was introduced following fatty (MAFLD). Both aim to address the limitations of nonalcoholic (NAFLD). This review analyzes similarities and differences between MAFLD MASLD, focusing on their impacts epidemiology, diagnosis, stigma, related diseases. Current evidence suggests that criteria effectively identify individuals at higher risk through a good balance sensitivity specificity. Moreover, is more generalizable term easily understood globally. The transition from NAFLD MASLD marks significant advance in understanding within hepatology. identifies homogeneous cohort patients with due dysfunction provides valuable framework for holistic, patient-centered management strategies consider various contributing factors improve health outcomes.

Язык: Английский

---

Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?

Singapore Medical Journal, Год журнала: 2025, Номер 66(4), С. 173 - 174

Опубликована: Апрель 1, 2025

Язык: Английский

---